Showing 5041-5050 of 20470 results for "".
- Understanding Parkinson’s Disease and the Brain’s Action Networkhttps://reachmd.com/news/parkinsons-disease-brain-action-network/2485644/For decades, Parkinson’s disease has been framed primarily as a disorder of movement—an illness rooted in malfunctioning motor circuits and defined by tremor, rigidity, and slowness. A
- Speed-Focused Cognitive Training With Booster Sessions Linked to Lower Dementia Diagnoses Over 20 Yearshttps://reachmd.com/news/speed-focused-cognitive-training-with-booster-sessions-linked-to-lower-dementia-diagnoses-over-20-years/2485634/Long-term follow-up data from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) study indicate that a specific form of cognitive training—speed of processing
- 4DMT Completes Enrollment in Phase 3 4FRONT-1 Trial Evaluating 4D-150 in Wet Age-Related Macular Degenerationhttps://reachmd.com/news/4front-1-enrollment-complete-what-clinicians-should-expect/2485629/4D Molecular Therapeutics (Nasdaq: FDMT) has completed enrollment in its 4FRONT-1 Phase 3 clinic
- Upadacitinib Shows Rapid, Durable Skin Pain Relief in Moderate-to-Severe Atopic Dermatitishttps://reachmd.com/news/upadacitinib-shows-rapid-durable-skin-pain-relief-in-moderate-to-severe-atopic-dermatitis/2485627/Poster data presented at Winter Clinical Hawaii indicated rapid and sustained reductions in skin pain among adults and adolescents with moderate-to-severe atopic dermatitis (AD) treated with upadacitinib. The analysis emphasized skin pain as a clinically meaningful
- A Whole-Face, Whole-Patient Framework Review for Aesthetic Consultationhttps://reachmd.com/news/a-whole-face-whole-patient-framework-review-for-aesthetic-consultation/2485626/Aesthetic facial rejuvenation is increasingly defined by comprehensive, patient-centered assessment rather than isolated correction of individual features, according to a multidisciplinary review published in Dermatologic Surgery. Drawing on insights from dermatology, plastic surgery, an
- South Beach Symposium: Dr. Neal Neal Bhatia Maps a Fragmented but Promising Pipelinehttps://reachmd.com/news/south-beach-symposium-dr-neal-neal-bhatia-maps-a-fragmented-but-promising-pipeline/2485624/At the 2026 South Beach Symposium, Neal Bhatia, MD, FAAD, delivered a wide-ranging and opinionated overview of the current dermatology therapeutic landscape, arguing that Innovation is uneven across disease states and increasi
- Exploring a Team-Based Psychoeducational Program for Primary Care Wellbeinghttps://reachmd.com/news/team-psychoeducational-primary-care-wellbeing/2485617/A large-scale psychoeducational initiative in Catalonia is shedding light on both the promise—and the limits—of emotional well-being programs for primary care teams. The Catalan Health Ins
- Climate, One Health Governance, and System Design: AMR Risks in the Western Pacifichttps://reachmd.com/news/climate-one-health-governance-and-system-design-amr-risks-in-the-western-pacific/2485606/Across the Western Pacific, climate-driven stressors are increasingly discussed as a “why now” amplifier of antimicrobial resistance (AMR) and related mortality. This update summarizes a mixed-methods systematic analysis linking temperature and rainfall changes with resistance genes
- Artemisia Extracts vs H1N1: Preclinical Mechanisms and Translational Next Stepshttps://reachmd.com/news/artemisia-extracts-vs-h1n1-preclinical-mechanisms-and-translational-next-steps/2485607/Three Artemisia plant extracts were tested against influenza A/H1N1 in a cell-based preclinical system, pointing to a potentially multi-modal development path that pairs virus-directed interference at entry and egress (hemagglutinin-mediated attachment and neuraminidase activity) wi
- Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitishttps://reachmd.com/news/reduced-dose-tralokinumab-maintains-symptom-control-for-up-to-1-year-in-atopic-dermatitis/2485613/Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April